Please enable JS

Investors

Press Releases

 
Press Releases
  Date Title View
Jun 21, 2004
CAMBRIDGE, Mass., June 21 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. announced today the pricing of its initial public offering of 5,350,000 shares of common stock at a price of $6.50 per share. All of the shares are being offered by Momenta. Momenta also granted to the underwriters a thirty-day option to purchase up to an a...
Jun 28, 2004
CAMBRIDGE, MA - June 28, 2004 – Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) announced today that the underwriters of the Company's recent initial public offering of 5,350,000 shares of common stock exercised in full their over-allotment option to purchase an additional 802,500 shares of common stock at the ini...
Jul 23, 2004
CAMBRIDGE, Mass., July 23 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) announced today that its Chairman and Chief Executive Officer Alan Crane will present at the Banc of America Securities "New Products, New Paradigms in Health Care" Conference on Friday, July 30, 2004 at 11:45 am Eastern Standard Time at the ...
Aug 16, 2004
CAMBRIDGE, Mass., Aug. 16 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on sugar sequencing technology, today announced its financial results for the quarter ended June 30, 2004. The Company reported a net loss of $2.9 million for the quarter ended June 30, 2004 com...
Sep 2, 2004
CAMBRIDGE, Mass., Sept. 2 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on sugar sequencing technology, announced today that its Chairman and Chief Executive Officer Alan Crane will present at the Bear Stearns 17th Annual Healthcare Conference on Monday September 13...
Sep 14, 2004
CAMBRIDGE, Mass., Sept. 14 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on sugar sequencing technology, announced today that its Chairman and Chief Executive Officer, Alan Crane, will present at the ThinkEquity Partners Growth Conference on Tuesday, September 21, 2...
Sep 16, 2004
CAMBRIDGE, Mass., Sept. 16 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) announced today that it will be included in the Russell 3000 Index when the Index is reconstituted effective October 1, 2004 to reflect companies who have recently completed successful initial public offerings (IPOs). Momenta completed its ...
Oct 12, 2004
Article Highlights the Potential of Sugars for Therapeutic Drug Development CAMBRIDGE, Mass., Oct. 12 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on sugar sequencing technology, announced today the publication of "Glycomics: A Pathway to a Class of New and...
Oct 28, 2004
CAMBRIDGE, Mass., Oct. 28 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on sugar sequencing technology, will report financial results for the third quarter 2004 on Friday, November 5, 2004 before the opening of the U.S. financial markets. Management will...
Oct 29, 2004
CAMBRIDGE, Mass., Oct. 29 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on sugar sequencing technology, announced today that its Chairman and Chief Executive Officer, Alan Crane, will present at the CIBC World Markets Fifteenth Annual Healthcare Conference on Monday...
1
...
NextLast
= add release to Briefcase